A First-in-Man Study of IBS

NCT ID: NCT03509142

Last Updated: 2025-04-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-10
• Study Completion Date: 2023-12-10

Brief Summary

The study is a pilot clinical trial for Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System（IBS）. The main purpose of this study is to evaluate the feasibility, preliminary safety and efficacy of IBS. To provide the basis for subsequent large-scale, multi-center, randomized controlled clinical trials of IBS.

Detailed Description

A prospective, single-center, First-in-Man trial;

Study population: 45 subjects.

45 subjects will be randomly assigned into two cohorts: cohort 1(n=30), cohort 2(n=15)

The clinical follow up will be performed in all subjects at 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years post procedure;

The Angiographic, Intra-Vascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be performed at 6 months and 2 years post procedure in cohort 1. The Angiographic, IVUS and OCT will be performed at 1 year and 3 years post procedure in cohort 2.

The primary study endpoints:

1. Target lesion failure (TLF) at 6 months post procedure

2. Late Lumen Loss at 6 months post procedure

Conditions

Single Coronary Vessel Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IBS implantation

Implantation of IBS in patients with coronary artery lesions. All the subjects will be assigned to cohort 1 (n=30) and cohort 2 (n=15).

Group Type: EXPERIMENTAL

Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System

Intervention Type: DEVICE

Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)

Interventions

Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System

Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)

Intervention Type: DEVICE

Other Intervention Names

IBS

Eligibility Criteria

Inclusion Criteria

All patients participating in this clinical trial must meet the following criteria:

1. Age of 18-75, males or non pregnancy females;

2. Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, post-infarct angina or silent ischemia) suitable for elective PCI;

3. One target lesion, and target lesion can be completely covered by a single stent;

4. Target lesion length ≤ 18 mm, target lesion diameter between 3.0 mm to 3.5 mm (visual);

5. Visual assessment of target lesion stenosis ≥70%, TIMI blood flow≥ 1;

6. Subject who understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up.

Exclusion Criteria

Patients will be excluded if any of the following conditions apply:

General:

1. Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal;

2. Implantation of stent in target vessel within 1 year, patients with planned intervention again within six months;

3. Patients who had coronary artery bypass (coronary artery bypass grafting);

4. Patients with contraindications for coronary artery bypass graft surgery;

5. Severe heart failure (NYHA class III and above) or left ventricular ejection fraction<40% (ultrasonic or left ventricular angiography);

6. Preoperative renal function: serum creatinine > 2.0 mg/dl or 177 mu mol/L; receiving hemodialysis;

7. Patients had ischemic stroke half a year before implantation, patients had transient ischemic attack 3 months before implantation, patients have high coagulation tendency judged by investigator or laboratory examination;

8. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage, contraindications on antiplatelet agents and anticoagulant therapy; patients would not allow to undergoing antithrombotic therapy;

9. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer, rapamycin and metal allergies;

10. Patients who have a history of disease related to iron overload or iron disorder, such as hereditary hemochromatosis, etc;

11. The patient's life expectancy is less than 12 months;

12. Patient participated in other drug or medical device study and does not meet the primary study endpoint in clinical trials time frame;

13. Poor compliance and patients unable to complete the study in accordance with the requirements;

14. Patient with heart transplant;

15. The unstable arrhythmia, such as high risk ventricular extra systole and ventricular tachycardia;

16. Cancer needs chemotherapy;

17. Patients of immune suppression, autoimmune diseases, planned or undergoing immunosuppressive therapy;

18. Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc;

19. With six months for elective surgery requires stop using aspirin and clopidogrel;

20. Blood test prompted platelet count < 100 x 10^9/L, or > 700 x 10^9/L, white blood cells < 3 x 10^9/L, or abnormal liver function (ALT, AST 3 times greater than normal range);

21. Patients with diffuse peripheral vascular disease; cannot use 6F catheter;

22. Patients with valvular surgery in the past.

1. Chronic total occlusion (TIMI blood flow=0 before implantation) , left main coronary artery lesion, ostial lesion, multiple vessel lesion, branch lesion and bridge lesion which branch vessel diameter ≥ 2.0 mm (if the ostium of branch vessel stenosis >40% or needs balloon predilation); visible thrombus in target vessels;

2. Severe calcified lesions and distorted disease which unable to predilation, lesion not suitable for stent delivery and expansion;

3. In-stent restenosis;

4. Myocardial bridge is involved in target lesion;

5. In order to reach the target lesion, study stent has to go through the previous implanted stent;

6. Predilation balloon can't expand completely in target lesion site, judgment standard for fully expansion as below, patients are excluded when do not meet any item:

A.DS% < 40% (visual), highly recommend DS% ≤20% B.TIMI blood flow= class 3 (visual) C.No angiography complications (e.g., distal embolization, lateral branch closed) D.No interlining level NHLBI type D - F E.No continuous chest pain (> 5 minutes), and F.No lower or higher ST segment >5 minutes.

-

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Lifetech Scientific (Shenzhen) Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Runlin Gao

Role: STUDY_CHAIR

Fu Wai Hospital, Beijing, China

Locations

Beijing Fuwai hospital

Beijing, , China

Countries

China

Other Identifiers

IBS-FIM

Identifier Type: -

Identifier Source: org_study_id